- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07481188
Frailty and Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery
Incremental Prognostic Value of Frailty Beyond the Nottingham Hip Fracture Score for Predicting 90-Day Mortality After Hip Fracture Surgery: A Prospective Cohort Study
Hip fractures are serious injuries that occur mostly in older adults. Many people experience health problems or may die in the months after surgery. Doctors try to identify patients who have a higher risk of poor outcomes as early as possible.
Doctors often use the Nottingham Hip Fracture Score (NHFS) to estimate the risk of death after hip fracture surgery. This score uses information such as age and other health conditions. However, it does not fully reflect how physically vulnerable a person may be.
Another important concept is frailty. Frailty describes how strong or weak a person's overall health and physical reserve are. In this study, frailty will be measured using the Clinical Frailty Scale (CFS). This scale evaluates a person's level of independence and physical function before the fracture.
The purpose of this study is to determine whether measuring frailty can improve the prediction of death after hip fracture surgery.
Older adults with hip fractures who undergo surgery will be invited to participate in the study. Researchers plan to include about 200 participants or all eligible patients enrolled within one year, whichever occurs first. Health information that is already collected during routine hospital care will be recorded. Frailty will be assessed when participants are admitted to the hospital.
Participants will be followed for 30 days and 90 days after surgery to determine survival status. Researchers will review hospital records and may contact participants or their relatives by phone if needed.
The results of this study may help doctors better identify patients at higher risk and improve care planning after hip fracture surgery.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hip fractures in older adults are associated with substantial morbidity, loss of independence, and high early mortality. Identifying patients at increased risk of poor outcomes is therefore an important part of perioperative care and treatment planning. Several clinical tools have been developed to estimate short-term mortality following hip fracture surgery. Among these, the Nottingham Hip Fracture Score (NHFS) is widely used and has been validated in multiple patient cohorts.
The NHFS is calculated using routinely available clinical variables such as age, comorbid conditions, and laboratory values. Although this score performs reasonably well in predicting short-term mortality, it mainly reflects comorbidity burden and demographic factors. It does not directly measure the patient's physiological reserve or overall vulnerability to stress.
Frailty has gained increasing attention as an important determinant of surgical outcomes in older adults. Frailty represents a state of reduced physiological reserve that limits the ability to recover from acute health events such as trauma or surgery. The Clinical Frailty Scale (CFS) is a practical bedside tool that classifies frailty based on functional status and the level of independence prior to illness or injury. Because it can be applied quickly in routine clinical settings, it has been used in various studies evaluating outcomes in geriatric populations.
Despite growing interest in frailty assessment, its added value when combined with established hip fracture risk scores remains uncertain. In particular, there is limited prospective evidence examining whether frailty assessment improves mortality prediction beyond existing tools such as the NHFS.
This prospective observational cohort study will collect standardized clinical data from older adults undergoing surgical treatment for proximal femoral fractures. Frailty will be assessed at hospital admission using the Clinical Frailty Scale based on the participant's functional status before the fracture. The Nottingham Hip Fracture Score will be calculated from routinely recorded clinical variables.
The analysis will examine the relationship between NHFS, frailty status, and short-term mortality following surgery. Predictive models including NHFS alone will be compared with models that incorporate both NHFS and frailty status in order to determine whether frailty provides additional prognostic information.
Understanding whether frailty assessment improves risk prediction may help clinicians identify vulnerable patients earlier and support more individualized perioperative management in older adults with hip fractures.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Eşref SELÇUK Asst Prof, MD
- Phone Number: +905356319974
- Email: trkesref@hotmail.com
Study Locations
-
-
-
Edirne, Turkey (Türkiye)
- Recruiting
- Trakya University
-
Contact:
- Eşref Selçuk Asst Prof Selçuk, MD
- Phone Number: +905356319974
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 60 years or older
- Admission for acute proximal femoral fracture (femoral neck, intertrochanteric, or subtrochanteric fracture)
- Surgical treatment for hip fracture
- Ability to obtain clinical data required for NHFS and frailty assessment
Exclusion Criteria:
- Pathological fractures
- Periprosthetic fractures
- Hip fractures resulting from high-energy trauma or polytrauma
- Non-operative treatment
- Second hip fracture occurring in the same patient during the study period
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Hip Fracture Surgery Cohort
Older adults aged 60 years or older who undergo surgical treatment for proximal femoral fractures.
Frailty will be assessed using the Clinical Frailty Scale and mortality outcomes will be evaluated at 30 and 90 days after surgery.
|
no intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
90 Day All Cause Mortality
Time Frame: 90 days after surgery
|
All cause mortality occurring within 90 days after hip fracture surgery.
|
90 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30 Day All Cause Mortality
Time Frame: 30 days after surgery
|
All cause mortality occurring within 30 days after hip fracture surgery.
|
30 days after surgery
|
|
Postoperative complications
Time Frame: 90 days after surgery
|
90 days after surgery
|
|
|
Length of hospital stay
Time Frame: From hospital admission to hospital discharge (up to 30 days)
|
From hospital admission to hospital discharge (up to 30 days)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Maxwell MJ, Moran CG, Moppett IK. Development and validation of a preoperative scoring system to predict 30 day mortality in patients undergoing hip fracture surgery. Br J Anaesth. 2008 Oct;101(4):511-7. doi: 10.1093/bja/aen236. Epub 2008 Aug 21.
- Narula S,Lawless A,D'Alessandro P,Jones CW,Yates P,Seymour H
- Kennedy MJ,Penfold RS,Donaldson L,Hall AJ,Davison MJ,MacLullich AMJ,Walmsley P,Clement ND,Clarke JV
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TÜTF-GOBAEK 2026/81
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
McMaster UniversityRecruitingFrailty | Frailty Syndrome | Frail Older Adults | Frailty in AgingCanada
-
Universidad Francisco de VitoriaNot yet recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric Health
-
Universidad Francisco de VitoriaActive, not recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric HealthSpain
-
University of IcelandLandspitali University HospitalRecruitingFrailty Syndrome | Elective Surgery | Frailty in Adult SurgeryIceland
-
Universidad Francisco de VitoriaNot yet recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric Health
-
Ji Yan Biomedical Co., Ltd.YC Biotech Co., Ltd.Not yet recruiting
-
University of NottinghamRecruitingFrailty | Diet | Systemic Inflammatory Response | Dietary Fiber | Frailty at Older Adults | Pre-FrailtyUnited Kingdom
-
Maximilian KönigNot yet recruiting
-
Instituto Tecnologico y de Estudios Superiores...Not yet recruiting
Clinical Trials on No Intervention: Observational Cohort
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
Institut Cancerologie de l'OuestNot yet recruiting
-
University of CalgaryRecruiting
-
Guangzhou Women and Children's Medical CenterNot yet recruitingNEC - Necrotizing Enterocolitis
-
Centre Leon BerardNutricia, Inc.Not yet recruitingSmell Disorder | Taste Alterations | Eating Behavior ChangesFrance
-
Washington University School of MedicineVanderbilt University Medical Center; University of Abuja Teaching HospitalNot yet recruitingPreeclampsia (PE) | Cardiovascular Biomarkers | Preeclampsia (PE) RiskNigeria
-
Heinrich-Heine University, DuesseldorfRoche Pharma AG; Maria Hilf Clinics GmbH, Mönchengladbach; German Multiple Sclerosis...RecruitingMultiple Sclerosis | Fatigue Syndrome, Chronic | Sleep Disorders | Primary Progressive Multiple Sclerosis | Secondary Progress Multiple Sclerosis | Remitting-Relapsing Multiple SclerosisGermany
-
Instituto de Investigación Sanitaria de la Fundación...Hospital General Universitario Gregorio Marañon; Fundació d'investigació Sanitària... and other collaboratorsRecruiting
-
The First Hospital of Jilin UniversityNot yet recruitingCritical Illness | Adult | ICU
-
The Children's Hospital of Zhejiang University...Not yet recruitingPediatric | Congenital Hydronephrosis | UTD Grading System | Natural ProgressionChina